NASH Pipeline: Racing To The Finish
As industry closes in on the first approved drug therapy for non-alcoholic steatohepatitis, our infographic details the dozens of companies testing numerous mechanisms for the multi-factorial disease.
You may also be interested in...
Swiss pharma thinks targeted integrin inhibition could be part of the approach to treating cirrhotic NASH patients, those most at risk of needing a liver transplant.
A month after Genfit’s Phase III failure, Inventiva hits multiple endpoints in a Phase IIb study of pan-PPAR agonist lanifibranor – likely drawing partnering or acquisition interest. Ascletis offers Phase II evidence for its NASH drug.
Emerging Company Profile: Axcella uses Generally Recognized As Safe (GRAS) amino acids to create drug candidates for hepatic encephalopathy, NASH and other diseases.